Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

Bayer AG

06/05/2026 07:43

May 6 (Reuters) - Bayer BAYGn.DE said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline.

The deal has a potential value of up to $2.45 billion, the company said in a statement, with a $300 million upfront payment and additional development, regulatory and commercial milestone payments based on success criteria.

(Reporting by Linda Pasquini
Editing by David Goodman
)

((linda.pasquini@thomsonreuters.com; +48 58 7785261;))